Argenx Eyes Hat-Trick Of Successful Launches For Vyvgart After CHMP Thumbs-Up

Myasthenia Gravis Drug Recommended For Approval

Anant Murthy, general manager of Argenx Europe, tells Scrip that the commercial infrastructure is in place for Vyvgart to enjoy a strong launch for the rare neuromuscular disorder which will mirror those seen in the US and Japan.

Traveller
Argenx set to target the EU's many markets • Source: Shutterstock

More from New Products

More from Scrip